Literature DB >> 7886394

Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success.

J Labenz1, F Leverkus, G Börsch.   

Abstract

BACKGROUND: Omeprazole plus amoxicillin may cure Helicobacter pylori infection. However, the published results vary rather widely, and the factors influencing the treatment success remain unclear.
METHODS: Four hundred and twenty-three H. pylori-positive patients were treated with 1- or 2-week regimens comprising 40 mg or 80 mg omeprazole and amoxicillin in 11 prospective protocols. A complete set of data was available for 405 patients (ulcer disease, n = 383; dyspepsia, n = 22) and was submitted to uni- and multi-variate statistical analyses to elucidate the factors affecting the cure rates of the infection; 18 patients were lost to follow-up.
RESULTS: The overall proportion of H. pylori cure was 76%. Insufficient compliance (p < 0.001), a short duration of treatment (p < 0.001), smoking (p = 0.003), and omeprazole pretreatment (p = 0.041) were the significant independent factors predicting treatment failure, whereas advanced age (p = 0.002), high scores of grade and of activity of gastritis (p = 0.035 and p = 0.019, respectively), and gastric ulcer disease (p = 0.058) were independent factors predicting treatment success.
CONCLUSIONS: Several patient- and therapy-related factors diminish or increase the rate of H. pylori cure obtained by omeprazole/amoxicillin. These should be considered in future studies comparing different treatment regimens for curing H. pylori infection and also when designing treatment regimens applicable for routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7886394     DOI: 10.3109/00365529409094890

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  27 in total

1.  Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.

Authors:  G Manes; O Pieramico; F Perri; D Vaira; N Giardullo; M Romano; G Nardone; A Balzano
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 2.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

3.  Eradication rate of Helicobacter pylori.

Authors:  J Labenz; B Tillenburg; U Peitz; H Köhl; G Börsch
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

4.  Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.

Authors:  P Moayyedi; D M Chalmers; A T Axon
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

5.  Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.

Authors:  G R Tennvall; A Norinder; B Ohlin
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

6.  Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial.

Authors:  Chien-Ying Lee; Hung-Che Shih; Min-Chien Yu; Ming-Yung Lee; Ya-Lan Chang; Ya-Yun Lai; Yi-Ching Lee; Yu-Hsiang Kuan; Chun-Che Lin
Journal:  Chin J Integr Med       Date:  2016-10-19       Impact factor: 1.978

Review 7.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

8.  Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.

Authors:  L J van Doorn; P M Schneeberger; N Nouhan; A P Plaisier; W G Quint; W A de Boer
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

9.  Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats.

Authors:  P V Sherwood; J I D Wibawa; J C Atherton; N Jordan; D Jenkins; D A Barrett; P N Shaw; R C Spiller
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Authors:  Seung Bae Yoon; Jae Myung Park; Jong-Yul Lee; Myong Ki Baeg; Chul-Hyun Lim; Jin Soo Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Myung-Gyu Choi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.